WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1996007417) METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1996/007417    International Application No.:    PCT/US1995/011335
Publication Date: 14.03.1996 International Filing Date: 06.09.1995
Chapter 2 Demand Filed:    27.03.1996    
IPC:
A61K 38/29 (2006.01)
Applicants: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US)
Inventors: BEVAN, John, Althorp; (US).
GEDDES, Ann, Dunbar; (US)
Agent: REED, T., David; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US)
Priority Data:
08/303,925 09.09.1994 US
Title (EN) METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE
(FR) PROCEDES DE TRAITEMENT DE L'OSTEOPOROSE UTILISANT DES PHOSPHONATES OSTEOACTIFS ET UNE HORMONE PARATHIROÏDIENNE
Abstract: front page image
(EN)The present invention provides methods of treating a human or other animal subject having a bone metabolism disorder, comprising the steps of: (a) administering to said subject a safe and effective amount of a bone active phosphonate during a period of at least about 6 months; (b) administering to said subject a safe and effective amount of a parathyroid hormone, during a period of from about 3 to about 12 months.
(FR)L'invention concerne des procédés de traitement d'un sujet humain ou d'un sujet animal présentant un dérèglement du métabolisme osseux, comprenant les étapes consistant: (a) à administrer audit sujet une dose efficace et sans danger d'un phosphonate ostéoactif pendant une durée d'au moins environ 6 mois, (b) à administrer audit sujet une dose efficace et sans danger d'une hormone parathyroïdienne, pendant une durée comprise entre environ 3 et environ 12 mois.
Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN.
African Regional Intellectual Property Organization (KE, MW, SD, SZ, UG)
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)